22:33 , May 2, 2019 |  BC Innovations  |  Product Development

Evelo breaks from the microbiome pack with non-colonizing bugs

While most companies developing bugs as drugs want their microbes to flourish in hosts, Evelo is designing microbial candidates that exert therapeutic effects without colonizing, replicating or metabolizing -- acting more like biologics than live...
21:30 , Mar 11, 2019 |  BC Extra  |  Company News

Seres, AZ partner on microbiome research to treat cancer, predict response

Seres gained $1.27 (25%) to $6.38 on Monday after it announced a three-year partnership with AstraZeneca to evaluate microbiome-based approaches to improve and predict patient response to immunotherapies. Seres Therapeutics Inc. (NASDAQ:MCRB) will receive $20...
18:37 , May 11, 2018 |  BC Week In Review  |  Financial News

Evelo raises $85M in IPO

Microbiome company Evelo Biosciences Inc. (NASDAQ:EVLO) raised on May 8 $85 million through the sale of 5.3 million shares at $16 in an IPO underwritten by Morgan Stanley, Cowen, BMO Capital Markets and JMP Securities....
15:41 , May 9, 2018 |  BC Extra  |  Financial News

Evelo raises $85M in IPO

Microbiome company Evelo Biosciences Inc. (NASDAQ:EVLO) raised $85 million through the sale of 5.3 million shares at $16 in an IPO underwritten by Morgan Stanley, Cowen, BMO Capital Markets and JMP Securities. Evelo added $0.25...
20:00 , Apr 20, 2018 |  Proposed Offerings  |  Proposed Offerings

Microbiome company Evelo proposes $100M IPO

Microbiome company Evelo Biosciences Inc. (Cambridge, Mass.) proposed on April 13 to raise $100 million in an IPO on NASDAQ underwritten by Morgan Stanley, Cowen, BMO Capital Markets and JMP Securities. Evelo has a portfolio...
22:08 , Apr 13, 2018 |  BC Extra  |  Financial News

Evelo proposes $100M IPO

Microbiome company Evelo Biosciences Inc. (Cambridge, Mass.) proposed to raise $100 million in an IPO on NASDAQ underwritten by Morgan Stanley, Cowen, BMO Capital Markets and JMP Securities. Evelo has a portfolio of preclinical monoclonal...